https://www.selleckchem.com/products/hg6-64-1.html
4±2.2h. For the patient requiring CVVH, clearance and t were 22.5mL/min and 9.5h, respectively. Mean levetiracetam CL during SLED performed at a blood flow rate of 250mL/min and a dialysate flow rate of 100mL/min was 74.0±25.3mL/min and t was 4.8±2.3h. Levetiracetam clearance was substantial with both modalities under the operating conditions reported. There is the potential for subtherapeutic concentrations with current recommended dosing strategies that account only for kidney function and not these extracorporeal routes of eliminati